The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.
Price target range & 52-week position
Bear¥193.90Fair value¥1,014.68Bull¥1,830.04
FairClose
52-week traded range
52W low ¥1,062.0052W high ¥1,725.00
The 52-week range is measured from the stored price history, not estimated.
Valuation summary
Trading close to the consensus fair value
KYORIN Pharmaceutical Co.,Ltd. closed at ¥1,091.00, 7.5% above the consensus fair value of ¥1,014.68 drawn from 9 valuation models.
Financial DNA score 53/100 — Good. P/E of 18.2x against the 20x sector multiple the P/E model uses.
Quantitative summary only — not investment advice.
All valuation models
DCF Valuation
¥821.32
-24.7%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=8%, r=10%, tg=3%, n=10yr
Graham Number
¥1,830.04
+67.7%
√(22.5 × EPS × BVPS)
EPS=60.03, BVPS=2479.55
P/E Fair Value
¥1,200.60
+10.0%
EPS × 20x (sector P/E)
EPS=60.03, Sector P/E=20x
Peter Lynch (PEG)
¥193.90
-82.2%
EPS × Growth% (PEG = 1 is fair)
EPS=60.03, g=3.2%
EV/EBITDA
¥1,031.65
-5.4%
(EBITDA × 10x − Net Debt) ÷ Shares
EBITDA=8.23B
Dividend Discount (DDM)
¥726.12
-33.4%
D1 ÷ (r − g) where D1 = D0×(1+g)
D0=56.95, r=10%, g=2%
Book Value (P/B)
¥619.89
-43.2%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=2479.55, ROE=2.5%, g=3%, r=10%
Reverse DCF
¥1,091.00
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 5.9% | Historical: -3.2%
Margin of Safety
¥962.99
-11.7%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=1283.99, MoS=25%
Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.
Educational data only. Not a recommendation to buy, sell or hold any security.